Viking Therapeutics ($VKTX) is positioned to benefit from the growing obesity treatment market, with potential blockbuster drugs that could rival GLP-1 competitors like Ozempic. Key risks include clinical trial failures, regulatory setbacks, and intense competition from established players with larger resources.